Loading
Canopy Growth Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 23 Sept 2025.
Canopy Growth Corp: what insiders have been doing
Canopy Growth Corp belongs to the Food & Agriculture sector. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 29 filings signed by 7 insiders.
No insider bought on the market over the period, while 7 insiders filed 21 sales totalling €134k. The totals do not cover 7 filings with an undisclosed amount. Stewart Thomas Carlton filed the largest sale, €21k, on 17 September 2026, which represents 0.0057% of the company's market value.
Across the 5,812 companies tracked on its exchange, the median is 19 filings; at 29 filings, this issuer sits above that mark. Since 2021, the database holds 1 purchase and 68 sales by insiders of the company. The 10-K for the year ended 31 March 2026 shows 284.6 m CAD of revenue and -262.9 m CAD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at Village Farms International, Inc. and Orkla ASA also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
143
Thresholds
n/a
Buy Volume
€42,364
1 ops. · all time
Sell Volume
€1M
68 ops. · all time
Who traded when
BuySaleDavid Angelo Lazzarato8 sales
Theresa Yanofsky8 sales
Christelle Gedeon4 sales
Luc Mongeau1 buy3 sales
M. Shan Atkins4 sales
Thomas Carlton Stewart4 sales
+2 other insiders
Since the insiders bought
- -34.6%Entry US$1.42 · Close at T+365 US$0.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,648 of 24,148 companies
10.2
score / 100
Value6
Quality14
FCF yld-22%
Earn yld-82%
EV/EBITDA·
ROE-40%
Gross mgn24%
Net mgn-92%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$0.71
Analyst consensus
1 analysts2.50/5
US$1.20Target US$1.20(+67%)US$1.20
Income statement
RevenueUS$284.6M
Gross profitUS$69.7M24% margin
EBITDA-US$188.2M-66% margin
Net income-US$262.9M-79.2% margin
Valuation
PER (forward)-4.2x
P/Book0.6x
Beta2.37
Balance sheet & cash
Market capUS$321.1M
Total debtUS$278.7M
Free Cash Flow-US$69.8M
Debt / Equity40%
Profitability & ownership
ROE-39.5%
ROA-3.9%
% insiders0.2%
% institutions7.8%
Last declaration on 30 September 2026
Declarations143 total
3,096 shares@ US$0.92680.0007% mcap54.1% of flowCommon SharesSEC:0001104659-26-112361:0
14,920 shares@ US$0.92680.0033% mcap5.1% of flowCommon SharesSEC:0001104659-26-112364:0
22,380 shares@ US$0.92680.0050% mcap6.5% of flowCommon SharesSEC:0001104659-26-112362:0
3,096 shares@ US$0.92680.0007% mcap35.1% of flowCommon SharesSEC:0001104659-26-112355:0
25,755 shares@ US$0.930.0057% mcap36.8% of flowCommon SharesSEC:0001104659-26-108651:0
2,231 shares@ US$1.470.0008% mcap4.9% of flowCommon SharesSEC:0001104659-26-100924:0
13,344 shares@ US$1.470.0045% mcap9.6% of flowCommon SharesSEC:0001104659-26-100926:0
3,197 sharesCommon SharesSEC:0001104659-26-078837:0
3,197 sharesCommon SharesSEC:0001104659-26-078842:0
22,674 sharesCommon SharesSEC:0001104659-26-078832:0
15,054 sharesCommon SharesSEC:0001104659-26-078840:0
162,485 sharesCommon SharesSEC:0001104659-26-076417:0
108,324 sharesCommon SharesSEC:0001104659-26-076419:0
108,324 sharesCommon SharesSEC:0001104659-26-076415:0
1,056,152 sharesCommon SharesSEC:0001104659-26-076407:0
135,231 sharesCommon SharesSEC:0001104659-26-076407:1
396,012 sharesCommon SharesSEC:0001104659-26-076410:0
58,994 sharesCommon SharesSEC:0001104659-26-076410:1
379,018 sharesCommon SharesSEC:0001104659-26-076411:0
9,285 sharesCommon SharesSEC:0001104659-26-076411:1
108,324 sharesCommon SharesSEC:0001104659-26-076413:0
2,658 shares@ US$0.93100.0% of flowCommon SharesSEC:0001104659-26-039176:0
15,624 shares@ US$0.934.8% of flowCommon SharesSEC:0001104659-26-039166:0
10,373 shares@ US$0.933.7% of flowCommon SharesSEC:0001104659-26-039179:0
2,074 shares@ US$0.9335.8% of flowCommon SharesSEC:0001104659-26-039178:0
25 of 143 declarations
About Canopy Growth Corp
Canopy Growth Corp. (ticker CGC) is a Canadian cannabis company listed in the United States on the Nasdaq market, with its corporate headquarters in Smiths Falls, Ontario, Canada. For French-speaking investors, it is one of the best-known names in the global cannabis industry, positioned at the intersection of medical cannabis, adult-use cannabis, and consumer products. The company emerged in the 2010s as Canada moved toward legalization and then expanded through a mix of brand building, acquisitions, and international licensing.
Canopy Growth’s business model is now organized around several complementary revenue streams. In Canada, it sells medical cannabis and, to a lesser extent, adult-use cannabis. Internationally, it serves medical patients in markets including Europe and Australia, with management highlighting activity in Germany, Poland, and Australia. Another important pillar is Storz & Bickel, the company’s vaporization-device business, which gives Canopy a more industrial, hardware-oriented exposure and a premium product platform. Its brand portfolio includes Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, alongside Storz & Bickel’s category-defining vaporization devices.
Read moreShow less
From a competitive standpoint, Canopy Growth remains one of the most recognized cannabis companies in North America, but it is also a company in transition. The strategic emphasis has shifted toward simplifying the operating footprint, improving profitability, and strengthening the balance sheet. That matters because the cannabis sector has remained highly competitive, regulation-driven, and financially demanding. Canopy’s brand strength and global medical reach are meaningful assets, but the company must continue to manage pricing pressure, uneven consumer demand, and regulatory complexity across jurisdictions.
Recent developments reinforce that balance-sheet repair and execution are the key investment themes. In 2025 and early 2026, Canopy Growth announced recapitalization steps, debt prepayments, and a new at-the-market equity program of up to US$200 million to enhance liquidity and financial flexibility. Its fiscal 2025 results showed improved Adjusted EBITDA and continued cost discipline, while management emphasized the integration of its medical cannabis operations into a single global platform. The company also reported that German medical cannabis performance benefited from a broader patient product portfolio. Overall, CGC remains a Nasdaq-listed cannabis exposure with recognizable brands and international reach, but the investment case is still centered on restructuring progress, margin recovery, and balance-sheet strength in the United States-listed capital market context.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
